We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The first patient has been enrolled in a phase 2 trial ...

PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported topline results from a Phase 2 clinical trial evaluating its ...

In a randomized trial, recurrence was higher after superficial curettage (SC) plus imiquimod cream than surgical excision (SE) in patients with nodular basal cell carcinoma (nBCC). At 5 years ...

Medicus Pharma Ltd. MDCX shares surged to a high of $1.61 before falling during Thursday’s premarket session following the release of topline data from its Phase 2 clinical trial for SKNJCT-003. The ...

The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe Philadelphia, ...

Please provide your email address to receive an email when new articles are posted on . AIV001 is a pan-tyrosine kinase inhibitor for the nonsurgical treatment of mixed basal cell carcinomas. Injected ...

Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.

Medicus Pharma Ltd. announced promising interim results from its SKNJCT-003 Phase 2 clinical study aimed at the non-invasive treatment of basal cell carcinoma (BCC) using the investigational product D ...

The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) The Company also announced that it is ...